Objectives: A consensus has existed on not to treat verocytotoxin-producing Escherichia coli (VTEC)-infected individuals with antibiotics because of possible subsequent increased risk of developing haemolytic uraemic syndrome (HUS). The aim of this systematic review is to clarify the risk associated with antibiotic treatment during acute VTEC infection and in chronic VTEC carrier states.
Introduction
Infection with verocytotoxin-producing Escherichia coli (VTEC), serotype O157:H7, was first reported in 1982. 1 Since then, there have been reports of new outbreaks and sporadic cases of VTEC infections worldwide and .400 VTEC serotypes have been linked to human disease. 2 Haemolytic uraemic syndrome (HUS) is a serious complication of VTEC infection and occurs in 5% -15% of cases, with children having the highest risk. HUS will frequently occur 5 -13 days after onset of diarrhoea with a mortality of between 3% and 5%. 3 The most significant virulence factors are the verocytotoxins VT1 and VT2 (Stx1 and Stx2) and the adherence factor intimin (eae). 4 -7 The verocytotoxins (tested in Vero cells) are also known as Shiga-like toxins, due to the similarity to the Shiga toxin produced by Shigella dysenteriae type 1.
Management of VTEC infection is symptomatic, which in severe cases includes haemodialysis. In general, it is recommended that patients with VTEC infection should not be treated with antibiotics owing to a possible risk of HUS. 8 -11 There are, however, case reports of carrier states lasting for .6 months. 12 Since post-symptomatic excretion of VTEC can be infectious, recommendations not to treat with antibiotics affects food handlers, healthcare workers, those who care for the elderly etc., who cannot return to work without a risk of infecting contacts or contaminating food items. 13, 14 The question remains whether treatment with antibiotics should be considered if certain criteria are met. More recent in vitro and in vivo studies provide a more nuanced picture regarding this issue.
Here, we systematically reviewed clinical studies as well as in vivo and in vitro studies providing a deeper understanding of this question. On this basis, adding data from the Danish national registry of VTEC infections including information about serotypes and virulence profiles, we discuss a possible antibiotic treatment regimen.
Methods
We reviewed the literature based on an article search in PubMed (http:// www.ncbi.nlm.nih.gov/pubmed) using the MeSH terms 'Antibiotic' AND 'Escherichia coli' AND 'Haemolytic uraemic syndrome'. In addition, a search for in vitro and in vivo studies was carried out using the MeSH terms 'Antibiotic' AND 'Escherichia coli' AND 'Verocytotoxin'. Articles were also found after scrutinizing reference lists and related citations. An additional search was performed using the MeSH terms 'Shiga toxin producing Escherichia coli' AND 'Antibiotic'; however, no new studies were included in our dataset based on inclusion and exclusion criteria. The inclusion criteria for clinical studies were: studies from 1982 -2013 evaluating the risk of HUS after antibiotic treatment. The exclusion criteria for clinical studies were: no clear definition of HUS, no clear diagnosis of VTEC, and no clear definition of time interval between antibiotics and VTEC infection. The inclusion criteria for in vitro and in vivo studies were: measuring of toxin levels in VTEC cultures after antibiotic exposure, and clinical outcome where VTEC-infected mice were treated with antibiotics. The exclusion criteria were: unclear results regarding antibiotic dosage and toxin release. Two PRISMA (http://www.prisma-statement.org/statement.htm) flow diagrams illustrate the outcome of the search (Figures 1 and 2 ). To provide further evidence, we included data on outcomes of VTEC infection in Danish patients, collected at the WHO Collaborating Centre for Reference and Research on Escherichia and Klebsiella, Department of Microbiology and Infection Control, Statens Serum Institut, Denmark. The dataset included patients from 1983 -2013 from the Danish national registry of VTEC infections. Cases were culture-confirmed patients with VTEC infections; all isolates were submitted from regional clinical microbiology departments to Statens Serum Institut. Strains were, among other confirmatory tests, also genotyped with the PCR protocol for subtyping of vtx genes. 15 
Results
The results section has been structured into: (i) a systematic review of key papers of published clinical studies investigating the relation between antibiotic treatment and the risk of HUS; (ii) studies clarifying the association between virulence factors and occurrence of HUS, adding data from the Danish national registry of VTEC infections; and (iii) in vitro studies of VTEC, its susceptibility to different antibiotics and degree of subsequent toxin release. One meta-analysis, 10 clinical studies and 22 in vitro/ in vivo studies were included in this review (Figures 1 and 2 ).
Risk of HUS in VTEC-infected patients treated with antibiotics
Our search revealed only one randomized trial of VTEC-infected patients that found no association between antibiotics and the risk of HUS. 16 The remaining studies were observational (casecontrol studies and prospective and retrospective cohort studies; Table 1 ). Exposure to trimethoprim/sulfamethoxazole was associated with increased incidence of HUS. 17 Treatment with sulfamethoxazole started ,3 days after onset of E. coli O157 diarrhoea was likewise associated with HUS. 18 A prospective cohort study Systematic review 2441 JAC found that antibiotics increased the risk of HUS significantly in children with E. coli O157:H7 infection. In addition, in patients treated within 3 days from the onset of symptoms, the risk of developing HUS was higher. 19 A follow-up paper including children with E. coli O157:H7 infection was published in 2012. The previously described association was still present. 20 A retrospective study of E. coli O157-positive and hospitalized patients found that prehospital treatment with unspecified antibiotics ,4 weeks prior to symptom onset was associated with a higher incidence of HUS. 21 In a retrospective study, patients positive for O157 were identified over 5 years. The pre-hospital treatment was grouped by duration and effect against the isolated E. coli. In that study, a protective effect against HUS of appropriate antibiotics given for .24 h was found. 22 In a later paper (1994) from this group, using an extended cohort analysis and multivariate analysis, a positive effect of prolonged antibiotics was no longer significant. 23 A retrospective cohort study found no effect of antibiotics on the duration of VTEC infection or the development of HUS. 24 In a retrospective case -control study, children ,16 years of age were treated with antibiotics with at least two doses given within the first 3 days from onset of symptoms and no difference in the number of HUS cases was found between the groups. 25 In a nonrandomized prospective study, treatment with fosfomycin was associated with a low risk of HUS. 26 An age-matched case-case comparison study of individuals ,20 years of age with cultureconfirmed O157 infection with or without HUS was conducted. Subjects with HUS were more likely to have been treated with bactericidal antibiotics and less likely to have been treated with bacteriostatic antibiotics. 27 Among the included clinical studies, four studies found an increased risk of HUS, four studies found no altered risk of HUS and two studies found a protective effect of antibiotics. In a meta-analysis by Safdar et al., 9 examining whether antibiotic therapy for E. coli O157:H7 enteritis increases the risk of HUS, no association was found between antibiotics and HUS (pooled OR 1.15; 95% CI 0.79 -1.68). In the meta-analysis, six retrospective and three prospective studies met the inclusion criteria (all of these are included in our review). The studies were all based on serotype O157, some on tests for the vtx1 and vtx2 genes, but none with tests for the eae gene or vtx subtypes.
Serotypes and virulence factors
Overall, VTEC infection was complicated by HUS in 3.5% (70/2001) of the patients registered in the Danish national registry of VTEC infections; 6% (44/698) in children ≤5 years of age, 5% (12/229) in children aged 6 -14 years and 1% (14/1074) in patients aged Systematic review ≥15 years. However, great variation was found among different virulence types (Table 2) . VTEC without both vtx2 and eae is only sporadically associated with HUS. However, important exceptions are: (i) a large outbreak in 2011 of VTEC O104:H4 vtx2a positive and eae negative, but positive for many of the virulence factors found in enteroaggregative E. coli; 28 a certain subtype of vtx2 (vtx2d activatable) in eae-negative VTEC; 29 and a VTEC clone of serotype O103:H2, and virulence type vtx1 and eae.
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In vitro and mouse studies
In the 22 experimental studies, a total of 36 generic antibiotics were tested. They fell into three groups: DNA synthesis inhibitors, protein synthesis inhibitors and cell wall synthesis inhibitors. All studies but one (Table S1 , available as Supplementary data at JAC Online) tested two or more antibiotics and the effects on toxin release were stratified according to this. In certain studies, the effect was also stratified according to dosage, i.e. above or Systematic review 2443 JAC below the MIC, serotype and virulence profile. The effect of antibiotics was measured as free verocytotoxin in supernatants (in most studies), in cytotoxicity assays and as transcription activity for verocytotoxin mRNA. In five studies, 31 -35 VTEC-infected mice were treated with antibiotics and the effect was observed as mortality rate compared with controls, as physical condition after treatment/no treatment or as free verocytotoxin in stools. The effect of antibiotic is summarized in Table S1 and indicated with an arrow as increased verocytotoxin ( ), decreased verocytotoxin ( ) or no effect ( ).
Fluoroquinolones, mainly ciprofloxacin, were found to increase verocytotoxin in 13 of 18 studies. 6,29,31 -33,35 -47 Trimethoprim/ sulfamethoxazole increased verocytotoxin in three studies. 36, 40, 41 When trimethoprim/sulfamethoxazole was given to mice, the amount of free toxin in stools and mortality were increased compared with other antibiotics. 35 Treatment with protein synthesis inhibitors caused a decrease in verocytotoxin in 12 studies. 6,32,36 -38,40 -43,45,48,49 In treated mice, toxin in stools and mortality were reduced. 32, 35 Cell wall synthesis inhibitors increased toxin release in subtypes of VTEC in 8 of 11 studies. 32,36,38,40,42 -46,48,50 In treated mice, toxin concentration in faeces and mortality were reduced. 32, 33, 35, 47 In five studies, the RNA synthesis inhibitor combination rifaximin/rifampicin was tested and led to toxin increase, no effect (two studies) or toxin decrease. 34, 39, 42, 43, 45 In treated mice, the survival rate was significantly improved. 34 Several studies showed a higher verocytotoxin release when treating VTEC with antibiotics at less than their MIC, with variation in verocytotoxin release depending on serotype and virulence profile, i.e. vtx1, vtx2 or vtx1+ vtx2. 6,36,39 -43,48,50 -52 In conclusion, how VTEC responds to antibiotics in vivo and in vitro depends largely on: (i) the antibiotic class and dosage (below the MIC compared with at or above the MIC); and (ii) which virulence factors are represented in the bacterium (aggR, eae, vtx1, vtx2 or vtx1+ vtx2) and possibly the specific vtx subtype (Table S1 ).
Discussion
Considering the 10 clinical studies, 4 studies found an increased risk of HUS, 4 studies found no effect and 2 studies found a reduced risk of HUS. However, the two papers cited in favour of antibiotics have been either superseded by new data demonstrating no significant effect 23 or data seem to have been scrutinized until a subgroup appeared showing a positive effect of antibiotics. 26 Differences in association between antibiotics and HUS found in the clinical studies are probably explained by the great diversity of the studies. Importantly, different antibiotics were used. 6, 36, 40, 48 Two studies assessed the effect of prehospital antibiotic treatment, but types of antibiotic, indication for treatment, dosage and duration are unclear 21 or only superficially described. 22 Other studies described several types of antibiotic, but the effect was calculated either without differentiation between the antibiotic used 24, 25 or for individual types of antibiotic, resulting in a small number of treated patients. 24 In one study, 11 of the 50 antibiotic-treated patients were treated with more than one type of antibiotic. 25 In vitro studies have shown that increased toxin production by VTEC isolates primarily occurs after incubation with sublethal doses of antibiotics. 6, 36, 40, 48 Dosage of antibiotic is listed only in the randomized study by Proulx et al. 16 and in the retrospective studies it is inherently difficult to obtain valid data on dosage. The question is whether it is basically due to an inadequate treatment regimen that some studies have shown an increased risk of HUS among antibiotic-treated patients. Furthermore, the time of treatment initiation as measured from the onset of symptoms varied considerably in the different studies. The risk of HUS was in one study highest if antibiotic treatment was initiated within 3 days from the onset of symptoms. 19 Studies imply that the time interval from onset of symptoms to initiation of treatment plays a role. This has implications for the validity of the only randomized study of antibiotic treatment in VTEC, since randomization and treatment were first initiated at a median of 7 days after onset of symptoms. 16 Interestingly, only one case of HUS has to our knowledge been reported in patients with diarrhoea symptoms for .14 days. 3, 20, 52 In these clinical trials, confounding does occur if HUS-associated factors other than antibiotics are unevenly distributed between treated and untreated patients, such as age ,8 years, bloody diarrhoea and leucocyte count. 4,25,19 -21,25 In only four of the included studies was adjustment for severity of illness and other risk factors for HUS performed, with two showing no increased risk of HUS, one showing a clearly increased risk and one showing increased risk after pre-hospital antibiotics. 16,19 -21,25 Another possible, and important, explanation for the varying results in the clinical studies could be that the included cases are primarily based on serotyping and not full genotyping, and that different subgroups of O157 with various virulence factors will react differently to antibiotics. 6, 40 Based on the clinical studies, it is not possible to conclude for or against antibiotic treatment of infections with VTEC, while in vivo and in vitro studies reveal that how VTEC responds to antibiotic largely depends on: (i) the type and This patient with O55:H12 was initially treated with two antibiotics (ceftriaxone and penicillin), which after 2 days was changed to three other antibiotics (ampicillin, gentamicin and meropenem).
Systematic review dosage of antibiotic (below the MIC compared with at or above the MIC); and (ii) which virulence factors are represented in the bacterium (aggR, eae, vtx1, vtx2 or vtx1 +vtx2) and possibly the specific vtx subtype.
Based on the above, we recommend that antibiotic treatment of patients infected with VTEC may be considered safe when certain criteria are met:
(i) Confirmed absence in a faecal specimen of VTEC with a virulence profile where there has been substantial international evidence for association with HUS, i.e. VTEC of serotype O103:H2 positive for vtx1 and eae, any serotype of VTEC positive for vtx2 and eae, vtx2a in an enteroaggregative E. coli and vtx2d in an eae-negative E. coli strain. However, even if a patient becomes a long-term carrier of an HUS-associated VTEC and there is a social indication for VTEC eradication as mentioned above, it would (based on our review) seem feasible to treat with antibiotics. However, in such cases normal hydration is mandatory. Furthermore, antibiotic treatment should not be initiated until 2 weeks after the first isolation of an HUS-associated VTEC and identical types of VTEC should have been isolated in two separate specimens.
Regarding choice of antibiotic, the purpose of treatment is to eradicate VTEC from the intestine without initiating toxin production. We therefore suggest a protein synthesis inhibitor given orally for 3 days followed by a standard dose of a bactericidal drug upon determination of resistance, preferably a cell wall inhibitor for 7 days. To our knowledge, this has not led to complications such as HUS and no such case has been reported through the Danish notification system. Furthermore, in a small study, antibiotic treatment was given to nine persons who experienced serious social problems due to prolonged, asymptomatic carriage of non-O157 VTEC isolates with low risk of HUS based on virulence profile according to the Danish cohort. The long-term carriers were identified among 114 patients diagnosed with a VTEC infection during acute illness. Eradication of VTEC in this setting was successful and without complications. 53 Likewise, Nitschke et al. 54 treated a group of HUS-associated O104:H4-positive patients with azithromycin and observed that this treatment significantly shortened the duration of bacterial shedding compared with an untreated group.
Whether appropriate antibiotic treatment could reduce the duration of diarrhoea or reduce the number of patients with HUS during acute infection with an HUS-associated VTEC is still an unresolved question.
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